Literature DB >> 9486389

Serum antibodies to HIV-1 are produced post-measles virus infection: evidence for cross-reactivity with HLA.

P V Baskar1, G D Collins, B A Dorsey-Cooper, R S Pyle, J E Nagel, D Dwyer, G Dunston, C E Johnson, N Kendig, E Israel, D R Nalin, W H Adler.   

Abstract

Convalescent sera obtained from patients who were recently recovered from an acute measles virus infection were tested for the presence of anti-HIV-1 antibodies by Western blot analysis. While 16% (17/104) of control sera displayed reactive bands to a variety of HIV proteins, 62% (45/73) of convalescent sera demonstrated immunoreactive bands corresponding to HIV-1 Pol and Gag, but not Env antigens. This cross-reactivity appears to be the result of an active measles infection. No HIV-1 immunoblot reactivity (0/10) was observed in sera obtained from young adults several weeks after a combined measles, mumps, and rubella (MMR) vaccination. Interestingly, examination of anti-HLA typing sera specific for either class I and class II molecules revealed that 46% (19/41) of these sera contained cross-reactive antibodies to HIV-1 proteins. Absorption of measles sera with mixed lymphocyte reaction (MLR)-activated lymphocytes and/or HIV-1 recombinant proteins significantly decreased or removed the presence of these HIV-1-immunoreactive antibodies. Together, these findings suggest that the immune response to a natural measles virus infection results in the production of antibodies to HIV-1 and possibly autoantigens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9486389      PMCID: PMC1904900          DOI: 10.1046/j.1365-2249.1998.00488.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  39 in total

1.  Non-specificity of HTLV-III reactivity in sera from rural Kenya and eastern Zaire.

Authors:  R J Biggar; C Saxinger; P Sarin; W A Blattner
Journal:  East Afr Med J       Date:  1986-10

2.  HLA antigen contamination of commercial Western blot strips for detecting human immunodeficiency virus.

Authors:  J J Drabick; J R Baker
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

3.  ELISA HTLV retrovirus antibody reactivity associated with malaria and immune complexes in healthy Africans.

Authors:  R J Biggar; P L Gigase; M Melbye; L Kestens; P S Sarin; A J Bodner; P Demedts; W J Stevens; L Paluku; C Delacollette
Journal:  Lancet       Date:  1985-09-07       Impact factor: 79.321

4.  Giant cell formation in lymphoid tissues of monkeys inoculated with various strains of measles virus.

Authors:  K Yamanouchi; Y Egashira; N Uchida; H Kodama; F Kobune
Journal:  Jpn J Med Sci Biol       Date:  1970-06

5.  Microbial products induce autoimmune disease by an IL-12-dependent pathway.

Authors:  B M Segal; D M Klinman; E M Shevach
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

6.  Variations in Western blot banding patterns of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus.

Authors:  D S Burke; R R Redfield; P Putman; S S Alexander
Journal:  J Clin Microbiol       Date:  1987-01       Impact factor: 5.948

7.  Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity.

Authors:  R S Fujinami; M B Oldstone
Journal:  Science       Date:  1985-11-29       Impact factor: 47.728

8.  Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease.

Authors:  J M Andrieu; P Even; A Venet; J M Tourani; M Stern; W Lowenstein; C Audroin; D Eme; D Masson; H Sors
Journal:  Clin Immunol Immunopathol       Date:  1988-05

9.  Studies on leukocyte cultures in measles. II. Detection of measles virus antigen in human leucocytes by immunofluorescence.

Authors:  B O Osunkoya; G I Adeleye; T A Adejumo; L S Salimonu
Journal:  Arch Gesamte Virusforsch       Date:  1974

10.  Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC class II beta 1 domain. I. Monoclonal antibodies against the gp41-derived peptide and patients' sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome.

Authors:  H Golding; F A Robey; F T Gates; W Linder; P R Beining; T Hoffman; B Golding
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Frequency, causes, and new challenges of indeterminate results in Western blot confirmatory testing for antibodies to human immunodeficiency virus.

Authors:  Ming Guan
Journal:  Clin Vaccine Immunol       Date:  2007-04-04

Review 2.  Perspectives of Immune Therapy in Coronavirus Disease 2019.

Authors:  Armen Yuri Gasparyan; Durga Prasanna Misra; Marlen Yessirkepov; Olena Zimba
Journal:  J Korean Med Sci       Date:  2020-05-11       Impact factor: 2.153

Review 3.  Potential repurposed SARS-CoV-2 (COVID-19) infection drugs.

Authors:  Gamal El-Din A Abuo-Rahma; Mamdouh F A Mohamed; Tarek S Ibrahim; Mai E Shoman; Ebtihal Samir; Rehab M Abd El-Baky
Journal:  RSC Adv       Date:  2020-07-17       Impact factor: 4.036

Review 4.  Natural Scrub Typhus Antibody Suppresses HIV CXCR4(X4) Viruses.

Authors:  George Watt; Pacharee Kantipong; Thierry Burnouf; Cecilia Shikuma; Sean Philpott
Journal:  Infect Dis Rep       Date:  2013-05-15

5.  Routine childhood immunization may protect against COVID-19.

Authors:  Samar Salman; Mohamed Labib Salem
Journal:  Med Hypotheses       Date:  2020-03-25       Impact factor: 1.538

6.  HLA antibody repertoire in infants suggests selectivity in transplacental crossing.

Authors:  Dana M Savulescu; Michelle Groome; Susan C K Malfeld; Shabir Madhi; Anthonet Koen; Stephanie Jones; Vania Duxbury; Karine Scheuermaier; Debbie De Assis Rosa; Melinda Suchard
Journal:  Am J Reprod Immunol       Date:  2020-06-16       Impact factor: 3.886

7.  Common childhood vaccines do not elicit a cross-reactive antibody response against SARS-CoV-2.

Authors:  Ahmed Kandeil; Mokhtar R Gomaa; Ahmed El Taweel; Ahmed Mostafa; Mahmoud Shehata; Ahmed E Kayed; Omnia Kutkat; Yassmin Moatasim; Sara H Mahmoud; Mina Nabil Kamel; Noura M Abo Shama; Mohamed El Sayes; Rabeh El-Shesheny; Mahmoud A Yassien; Richard J Webby; Ghazi Kayali; Mohamed A Ali
Journal:  PLoS One       Date:  2020-10-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.